The tablets, a combination of 100mg aspirin and 15mg lansoprazole, are the first FDC drug in Japan to combine low-dose aspirin with a proton pump inhibitor.
The company said that number of patients taking low-dose aspirin for prevention of the recurrence of cerebral infarction or myocardial infarction is increasing.
As administration of low-dose aspirin may cause gastric or duodenal ulcers, preventing the onset of ulcers in these patients is important.
Patients with a history of gastric or duodenal ulcers are recommended to have a combined administration with a proton pump inhibitor.
Takeda director and senior vice president of Pharmaceutical Marketing Division Masato Iwasaki said patients who had experienced a cardiovascular event need to take low-dose aspirin in the long-term in order to prevent recurrence.
"We believe Takelda combination tablets can make a contribution to improved drug adherence among patients who have a history of gastric or duodenal ulcer and are taking low-dose aspirin together with Takepron," Iwasaki said.
"We strive to provide patients and medical practitioners with highly convenient therapeutic options."